Jupiter Life Line Hospitals Ltd (JLHL) — shareholding pattern, promoter holding, financials and share price

About Jupiter Life Line Hospitals Ltd (JLHL)

Jupiter Life Line Hospitals Ltd operates in the Hospital industry, within the Healthcare sector. It trades on the NSE as JLHL and on the BSE under scrip code 543980. Its ISIN is INE682M01012.

Incorporated in 2007, Jupiter Life Line Hospitals Limited is a multi-specialty tertiary and quaternary healthcare provider in the Mumbai Metropolitan Area (MMR) and western region of India. [1]

Jupiter Life Line Hospitals Limited is a multi-speciality healthcare provider based in Western India, with facilities in Thane, Pune, and Indore, and a new hospital in Dombivli. Their core business involves tertiary and quaternary medical services across over 30 specialties.

The company successfully completed a significant capex project, a 500-bed hospital in Dombivli, ahead of schedule, exemplifying efficient project execution strategies under budget constraints.

Listed peers in Hospital: Rainbow Childrens Medicare Ltd, Park Medi World Ltd, Healthcare Global Enterprises Ltd, Yatharth Hospital & Trauma Care Services Ltd, Kovai Medical Center & Hospital Ltd, Artemis Medicare Services Ltd.

Valuation & Returns

10 Jul 2026

At ₹1,440.8 a share on 10 Jul 2026, Jupiter Life Line Hospitals Ltd (JLHL) was valued at a price-to-earnings ratio of 48.66x against an industry P/E of 61.73x and a price-to-book of 6.12x on a book value of ₹235.5 per share as of Mar 2026. Solomo computes return on equity of 12.57% and return on capital employed of 13.76% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.

P/E
48.66x
Industry P/E
61.73x
P/B
6.12x
EPS (TTM)
₹29.61
Book value / share
₹235.5
ROE
12.57%
ROCE
13.76%
ROA
8.15%
Debt / equity
0.38x
Dividend yield
0.07%
EBITDA margin
25.39%
52-week range
₹1,152.05 – ₹1,618.15

Ratios are computed from filed results and the last recorded price. Not investment advice.

Financial Performance

Mar 2026

In the year ended Mar 2026, Jupiter Life Line Hospitals Ltd (JLHL) reported revenue of ₹1,500 crore, net profit of ₹194 crore and earnings per share of ₹29.59. That compares with revenue of ₹1,302 crore and net profit of ₹194 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.

In the quarter ended Mar 2026, revenue was ₹388 crore and net profit ₹50 crore (consolidated).

Consolidated annual results for Jupiter Life Line Hospitals Ltd (JLHL), Mar 2022 to Mar 2026. Revenue and net profit in ₹ crore; EPS in ₹ per share.
MetricMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue (₹ cr)7338931,0731,3021,500
Net profit (₹ cr)5173177194194
EPS (₹)10.0512.926.9429.4729.59
Compound annual growth for Jupiter Life Line Hospitals Ltd (JLHL). Stock price CAGR is price return and excludes dividends.
Measure5Y3Y1Y
Sales growth21.03%15.01%15.16%
Profit growth63.08%21.31%0.23%
Stock price CAGR--4%

Ownership Summary

Jun 2026

As of Jun 2026, promoters hold 40.91% of Jupiter Life Line Hospitals Ltd (JLHL) (unchanged from the previous quarter), foreign institutional investors (FII) hold 9.37% and domestic institutional investors (DII) hold 16.51%. Market capitalisation was ₹9,447 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2023.

Largest disclosed public shareholders in Jun 2026: SBI HEALTHCARE OPPORTUNITIES FUND 7.77%, JM FINANCIAL PRODUCTS LIMITED 3.42%, GOLDMAN SACHS FUNDS -GOLDMAN SACHSINDIA EQUITY P 2.75%, MIHIR WIRE INDUSTRIES PVT LTD 2.15%, SBI LIFE INSURANCE CO. LTD 2.01%, DR NAVIN RAMJI DAVDA 2%. Only stakes above the 1% disclosure threshold are named in filings.

QuarterPromoterPledgedFIIDIIPublic
Jun 202640.91%-9.37%16.51%59.09%
Mar 202640.91%-8.48%17.01%59.09%
Dec 202540.91%-8.48%17.43%59.09%
Sep 202540.91%-9.06%16.95%59.09%
Jun 202540.91%-9.77%15.82%59.09%
Mar 202540.91%-10.03%15.63%59.09%
Dec 202440.91%-10.04%15.74%59.09%
Sep 202440.91%-8.84%16.87%59.09%
Every quarter since Sep 2023 Filing data, not investment advice.